Stockreport

Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Belite Bio, Inc - American Depositary Shares  (BLTE) 
PDF Tinlarebant is Belite Bio’s orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (G [Read more]